Subscribe
e.g. organoids

Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T Cell Function

Researchers showed that the genetic disruption of SUV39H1, which encodes a histone-3, lysine-9 methyl-transferase, enhanced the early expansion, long-term persistence, and overall anti-tumor efficacy of human CAR T cells in leukemia and prostate cancer models.
[Cancer Discovery]
Abstract
Published In
NewslettersCell Therapy News
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News

FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T Cell Immunotherapies

[FDA] The FDA has received reports of T cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
Cell Therapy NewsNewsletters
Read more

Modular Chimeric Cytokine Receptors with Leucine Zippers Enhance the Antitumour Activity of CAR T Cells via JAK/STAT Signaling

[Nature Biomedical Engineering] Investigators showed that replacement of the extracellular domains of heterodimeric cytokine receptors in T cells with two leucine zipper motifs provided optimal Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling.
Cell Therapy NewsNewsletters
Read more

CAR+ T Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

[blood] The authors presented the clinicogenomic characterization of a CARTITUDE-4 patient who developed a CAR+ T cell lymphoma post cilta-cel. Diagnostic and staging workup included biopsy analyses and FDG-PET scan.
Cell Therapy NewsNewsletters
Read more
Brought to you by